Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina Haagenrud Schultz(Oslo University Hospital), Ingvild Hausberg Sørvoll(University Hospital of North Norway), Annika E. Michelsen(Oslo University Hospital), Ludvig A. Munthe(Anna Needs Neuroblastoma Answers), Fridtjof Lund‐Johansen(Anna Needs Neuroblastoma Answers), Maria Therese Ahlén(University Hospital of North Norway), Markus Wiedmann(Anna Needs Neuroblastoma Answers), Anne Hege Aamodt(Anna Needs Neuroblastoma Answers), Thor Håkon Skattør(Anna Needs Neuroblastoma Answers), Geir E. Tjønnfjord(Institute of Clinical Research), Pål André Holme(Oslo University Hospital)
New England Journal of Medicine
April 9, 2021
Cited by 1,502Open Access
Full Text

Abstract

We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). The patients were health care workers who were 32 to 54 years of age. All the patients had high levels of antibodies to platelet factor 4-polyanion complexes; however, they had had no previous exposure to heparin. Because the five cases occurred in a population of more than 130,000 vaccinated persons, we propose that they represent a rare vaccine-related variant of spontaneous heparin-induced thrombocytopenia that we refer to as vaccine-induced immune thrombotic thrombocytopenia.


Related Papers

No related papers found

Powered by citation graph analysis